medical research roundupFriday 17 July

GLP-1 offsets antipsychotic weight gain

Today's medical research brings a promising crossover: GLP-1 drugs, already known for diabetes and obesity, show real weight-loss benefit for schizophrenia patients battling antipsychotic side effects. Meanwhile, new data on focal prostate cancer therapy and air pollution's heart risks round out a day heavy on treatment and prevention angles.

In today's edition: Treatment crossover and Prevention & risk, plus quick bites.

Treatment crossover

A drug class best known for metabolic health is proving useful in psychiatry, and long-term cancer therapy data is filling gaps in treatment options.

Prevention & risk

Two studies sharpen risk prediction for sudden cardiac arrest and coronary heart disease, while cannabis use gets a closer look for cardiovascular harm.

Quick bites